NEW YORK -- Pfizer announced Thursday that it has begun studying a third dose of its COVID-19 vaccine, part of a strategy to guard against mutated versions of the coronavirus.
Health authorities say first-generation COVID-19 vaccines still protect against variants that are emerging in different parts of the world. But manufacturers are starting to prepare now in case a more vaccine-resistant mutation comes along.
Pfizer said it will offer a third dose to 144 volunteers, drawing from people who participated in the vaccine’s early-stage U.S. testing last year. It wants to determine if an additional booster shot given six to 12 months after the first two doses would rev up the immune system enough to ward off a mutated virus.
Pfizer and its German partner, BioNTech, also are tweaking their vaccine recipe. The companies are in discussions with U.S. and European regulators about a study to evaluate doses updated to better match variants such as the one first discovered in South Africa.